Stockscreener 앱 받기
239.65
3.00%
-7.40
시간 외 거래:
239.65
전일 마감가:
$247.05
열려 있는:
$245.19
하루 거래량:
727.09K
Relative Volume:
1.09
시가총액:
$14.81B
수익:
$1.01B
순이익/손실:
$581.90M
주가수익비율:
27.01
EPS:
8.8733
순현금흐름:
$50.57M
1주 성능:
+0.70%
1개월 성능:
+4.53%
6개월 성능:
+14.11%
1년 성능:
+47.93%
1일 변동 폭
$234.75
$245.23
1주일 범위
$234.75
$249.96
52주 변동 폭
$156.56
$250.74
Ascendis Pharma A S Stock (ASND) Company Profile
Compare ASND vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ASND
Ascendis Pharma A S
|
239.65 | 15.26B | 1.01B | 581.90M | 50.57M | 8.8733 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Ascendis Pharma A S Stock (ASND) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-03-16 | 재개 | Jefferies | Buy |
| 2026-01-28 | 개시 | Barclays | Overweight |
| 2025-11-18 | 개시 | Wolfe Research | Peer Perform |
| 2025-10-17 | 개시 | Raymond James | Strong Buy |
| 2025-07-03 | 재개 | Morgan Stanley | Overweight |
| 2025-05-05 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-04-16 | 개시 | RBC Capital Mkts | Outperform |
| 2025-01-07 | 개시 | UBS | Buy |
| 2024-09-05 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2024-06-25 | 업그레이드 | TD Cowen | Hold → Buy |
| 2024-05-31 | 개시 | Stifel | Buy |
| 2023-12-20 | 개시 | Jefferies | Buy |
| 2023-06-14 | 재개 | Credit Suisse | Neutral |
| 2023-04-05 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2023-04-04 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2023-04-03 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2022-10-20 | 개시 | Goldman | Buy |
| 2022-08-30 | 재개 | Berenberg | Buy |
| 2022-03-28 | 재개 | Wedbush | Outperform |
| 2022-03-15 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2022-03-01 | 개시 | Citigroup | Buy |
| 2022-02-14 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2022-01-06 | 개시 | Cowen | Market Perform |
| 2021-12-08 | 개시 | Wells Fargo | Overweight |
| 2021-10-20 | 다운그레이드 | BofA Securities | Buy → Neutral |
| 2021-03-30 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2021-03-11 | 재개 | Stifel | Buy |
| 2020-12-17 | 개시 | Berenberg | Buy |
| 2020-09-14 | 재개 | JP Morgan | Overweight |
| 2020-03-20 | 개시 | Oppenheimer | Outperform |
| 2019-10-11 | 개시 | Morgan Stanley | Overweight |
| 2019-03-25 | 개시 | Evercore ISI | Outperform |
| 2019-01-24 | 개시 | Cantor Fitzgerald | Overweight |
| 2019-01-24 | 업그레이드 | Leerink Partners | Mkt Perform → Outperform |
| 2018-06-26 | 개시 | Stifel | Buy |
| 2018-04-02 | 재확인 | Leerink Partners | Mkt Perform |
| 2017-05-11 | 개시 | JP Morgan | Overweight |
| 2017-03-09 | 다운그레이드 | Leerink Partners | Outperform → Mkt Perform |
| 2017-02-09 | 개시 | Credit Suisse | Outperform |
| 2016-09-26 | 개시 | Wedbush | Outperform |
모두보기
Ascendis Pharma A S 주식(ASND)의 최신 뉴스
Ascendis Pharma A/S (ASND) Stock Analysis: Riding the Wave of Impressive Revenue Growth and Analyst Optimism - DirectorsTalk Interviews
Ascendis Pharma’s Skytrofa gains FDA approval for growth hormone deficiency - MSN
ASNDAscendis Pharma A/S Stock Price and Quote - Finviz
Liquidity Mapping Around (ASND) Price Events - Stock Traders Daily
ASND Technical Analysis | Trend, Signals & Chart Patterns | ASCENDIS PHARMA A/S (NASDAQ:ASND) - ChartMill
ASND Price Today: Ascendis Pharma A/S Stock Price, Quote & Chart | MEXC - MEXC
What Does YUVIWEL's FDA Approval Mean for Ascendis Pharma - Kavout
Citigroup initiates coverage of Ascendis Pharma A (ASND) with buy recommendation - MSN
Ascendis Pharma Earnings Call Highlights Growth Momentum - TipRanks
ASND Initiates Coverage by Citigroup -- Announces Price Target o - GuruFocus
Ascendis Pharma A/SOrdinary Share (NQ: ASND - The Chronicle-Journal
Assessing Ascendis Pharma (ASND) Valuation After Recent Soft Trading And Perceived Discount - simplywall.st
Ascendis Pharma initiated with a Buy at Citi - TipRanks
Morgan Stanley Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Cuts Target Price to $240.5 - 富途牛牛
Which Is a Better Investment, Ascendis Pharma A/S or Biogen Inc. Stock? - AAII
Ascendis Pharma A/S (ASND) Stock Analysis: Impressive Revenue Growth and Strong Buy Ratings Signal a Promising Future - DirectorsTalk Interviews
ASCENDIS PHARMA A/S (NASDAQ:ASND) Screens as a High-Growth Momentum Candidate - ChartMill
ASND Maintained by Evercore ISI Group -- Price Target Raised to $329 - GuruFocus
Janus Henderson (NASDAQ: ASND) reports 3.72M ADS stake - Stock Titan
Evercore Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Raises Target Price to $329 - 富途牛牛
Ascendis Pharma price target raised to $329 from $324 at Evercore ISI - TipRanks
Statutory Earnings May Not Be The Best Way To Understand Ascendis Pharma's (NASDAQ:ASND) True Position - simplywall.st
We Think Shareholders Should Be Aware Of Some Factors Beyond Ascendis Pharma's (NASDAQ:ASND) Profit - 富途牛牛
Ascendis Pharma (NASDAQ:ASND) Is Posting Healthy Earnings, But It Is Not All Good News - Yahoo Finance
What to Know About This Fund’s $50 Million Exit From Ascendis Pharma - AOL.com
Capital International holds 2.01M shares of Ascendis Pharma (ASND) - Stock Titan
Ascendis Pharma grants 31,250 employee warrants at $237.65 per share By Investing.com - Investing.com India
Ascendis Pharma grants 31,250 employee warrants at $237.65 per share - Investing.com
Ascendis Pharma Issues New Employee Warrants, Keeps Large Pool Available for Future Grants - TipRanks
Ascendis Pharma (ASND) grants 31,250 new employee share warrants - Stock Titan
Major Insider Move Shakes Up Ascendis Pharma Investors - TipRanks
Ascendis Pharma A/S(ASND.US) Officer Sells US$4.64 Million in Common Stock - Moomoo
Ascendis Pharma (ASND) officer exits 19,460 shares in open-market sale - Stock Titan
Number of shareholders of Ascendis Pharma A/S – NASDAQ:ASND - TradingView
Number of shareholders of Ascendis Pharma A/S – GETTEX:A710 - TradingView
[144] Ascendis Pharma A/S SEC Filing - Stock Titan
ASND Maintained by Barclays -- Price Target Raised to $345 - GuruFocus
Why (ASND) Price Action Is Critical for Tactical Trading - Stock Traders Daily
Barclays Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Maintains Target Price $345 - 富途牛牛
Ascendis sells specific US voucher for close to USD 200m - medwatch.com
Ascendis Pharma price target raised to $345 from $342 at Barclays - TipRanks
Ascendis Pharma A/S (ASND) Stock Report: Analyst Ratings Suggest 24% Upside Potential - DirectorsTalk Interviews
Ascendis Pharma hits milestone posting EUR 25m profit - medwatch.com
Assessing Ascendis Pharma (ASND) Valuation After Recent Share Price Momentum - simplywall.st
Wells Fargo Maintains Ascendis Pharma A/S(ASND.US) With Buy Rating, Cuts Target Price to $326 - 富途牛牛
Ascendis Pharma A/S Q1 2026 earnings preview - MSN
Ascendis Pharma A/S (NASDAQ:ASND) Q1 2026 Earnings Call Transcript - Insider Monkey
Ascendis Pharma A/S (NASDAQ:ASND) Upgraded by Wall Street Zen to "Buy" Rating - MarketBeat
Ascendis Pharma (ASND) Profit Swing To €10.2 EPS Tests Earnings Quality Concerns - simplywall.st
Ascendis Pharma A S (ASND) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.98%
0.12%
자본화:
|
볼륨(24시간):